Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin

Slides:

Advertisements

Similar presentations

Dynamics of Cytomegalovirus (CMV) Plasma DNAemia in Initial and Recurrent Episodes of Active CMV Infection in the Allogeneic Stem Cell Transplantation.

Advertisements

How to Treat MDS without Stem Cell Transplantation

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination Bipin.

David Myerson, Gideon Steinbach, Ted A. Gooley, Howard M. Shulman

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation in Myelofibrosis

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Establishment of Definitions and Review Process for Consistent Adjudication of Cause- specific Mortality after Allogeneic Unrelated-donor Hematopoietic.

A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease Paul A. Carpenter,

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Sabina Kersting, Leo F. Verdonck

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial Lauri M. Burroughs, Eneida.

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated.

Statistical Considerations in Studies of Late Effects in HCT

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft- Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Blood and Marrow Transplant Handbook

Mammen Chandy Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders Lauri M. Burroughs, Akiko.

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Jason W. Chien, Lue Ping Zhao, Barry Storer, Paul J

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse:

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin A. Mario Marcondes, David Hockenbery, Marina Lesnikova, Charles A. Dinarello, Ann Woolfrey, Terry Gernsheimer, Mahmoud Loghman-Adham, David Gelmont, Barry Storer, John A. Hansen, H. Joachim Deeg Biology of Blood and Marrow Transplantation Volume 22, Issue 9, Pages 1596-1601 (September 2016) DOI: 10.1016/j.bbmt.2016.05.011 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Patient with steroid-refractory acute GVHD. (A) Sigmoidoscopic appearance before initiation of treatment with AAT. (B) After 7 doses of AAT (patient 4). Biology of Blood and Marrow Transplantation 2016 22, 1596-1601DOI: (10.1016/j.bbmt.2016.05.011) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 AAT levels and clearance. (A) Plasma concentrations in 12 patients treated with 8 infusions of AAT. (B) Concentrations of AAT in stool before and during the course of AAT therapy. (C) Calculated AAT clearance on the basis of plasma and stool concentrations (see Methods). Biology of Blood and Marrow Transplantation 2016 22, 1596-1601DOI: (10.1016/j.bbmt.2016.05.011) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Plasma TIM3 levels in patients in cohort 1 (solid line with black-circle data points) and cohort 2 (dotted line with white-square data points) over the duration of AAT treatment. Biology of Blood and Marrow Transplantation 2016 22, 1596-1601DOI: (10.1016/j.bbmt.2016.05.011) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Proportion of regulatory T cells in peripheral blood. Shown are results for 5 healthy control subjects (black dots) and in 11 AAT-treated patients before (day 0) AAT, after the second dose of AAT (day 3), and upon completion of AAT therapy (last). Biology of Blood and Marrow Transplantation 2016 22, 1596-1601DOI: (10.1016/j.bbmt.2016.05.011) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions